For laboratory research use only.
Human menopausal gonadotropin (hMG, menotropin) is a mixed gonadotropin preparation historically characterized by both follicle-stimulating and luteinizing activities. It is a preparation class defined by bioassay activities more than by a single synthetic sequence string.
What “menotropin” means
Menotropin preparations contain FSH and LH activities derived from specified biological sources in pharmaceutical history, with unit labeling tied to bioassay conventions. Reviews of hypopituitarism and gonadotropin therapy illustrate clinical contexts in which mixed or recombinant gonadotropins are discussed (hypopituitarism review; recombinant gonadotropins; gonadotropins overview). Research-catalog listings are laboratory reference materials under research-use terms.
Why mixed preparations need extra documentation
Single-analyte reagents are easier to file. Menotropin carries dual activity concepts. Experimental records should capture labeled FSH and LH activities, the unit system, and the lot code. Without those fields, later readers cannot tell whether two “hMG” arms were comparable.
Choosing among reproductive-axis tools
If the question targets gonadal FSH receptors, hCG alone is the wrong lever. If it targets LHCGR only, purified hCG or LH may be clearer than a mixed menotropin. If it targets pituitary GnRH receptors, gonadorelin or a GnRH agonist is the correct level. Axis literacy prevents category errors.
Sources
- Hypopituitarism. (Pituitary, 2006, PMID 17077946)
- Recombinant gonadotropins. (Curr Womens Health Rep, 2001, PMID 12112963)
- Gonadotropins. (2012, PMID 31644163)